盐酸坦洛新缓释剂联合龙金通淋胶囊治疗慢性前列腺炎疼痛症状的疗效

Clinical observation of Tamsulosin Hydrochloride combined with Longjin Tonglin Capsule in treating chronic abacterial prostatitis

目的:观察盐酸坦洛新缓释剂联合龙金通淋胶囊治疗慢性前列腺炎疼痛症状的疗效。方法:慢性前列腺炎NIH-CPSI疼痛评分≥14分的患者100例,随机分为治疗组(盐酸坦洛新缓释剂联合龙金通淋胶囊)和对照组(单用龙金通淋胶囊),每组50例,均连续用药4周。治疗前后分别观察NIH-CPSI、EPS。采用美国国立卫生研究院(NIH)制定的前列腺炎症状评分(CPSI)标准判定疗效。结果:治疗组总有效率为94.0%和对照组82.0%;治疗前、后NIH-CPSI总评分治疗组为(24.54±3.61)分和(5.11±2.26)分,对照组为(23.21±4.05)分和(7.68±2.86)分(P<0.05);治疗前后NIH-CPSI疼痛症状评分治疗组为(15.90±2.76)分和(4.31±3.02)分,对照组为(14.62±3.17)分和(8.52±2.96)分(P<0.05);且治疗组治疗后NIH-CPSI总分和疼痛评分改善均优于对照组(P<0.05)。两组患者均未报告不良事件。结论:盐酸坦洛新缓释剂联合龙金通淋胶囊治疗慢性前列腺炎疼痛症状疗效满意,有良好的安全性和耐受性。

Objective： To observe the efficacy and safety of Tamsulosin Hydrochloride combined with Longjin Tonglin Capsule in treating chronic abacterial prostatitis.Methods： 50 patients in the trial group were treated with Tamsulosin Hydrochloride combined with Longjin Tonglin Capsule,and 50 patients in the control group were treated with Longjin Tonglin Capsule only.The NIH-CPSI and EPS were observed before and after a 4-week treatment.The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index（CPSI）.Results： The total improved was 94.0% in the trial group and 82.0% in the control group（P0.05）;Before and after treatment,the total NIH-CPSI score in the trail group was（24.54±3.61） and（5.11±2.26）,in the control group was（23.21±4.05） and（7.68±2.86）（P 0.05）;Before and after treatment NIH-CPSI pain score was（15.90±2.76） and（4.31±3.02） in the trail group,（14.62±3.17） and（8.52±2.96）（P0.05） in the control group;It was improved more significantly（P0.05） for NIH-CPSI total score and pain score in the trail group after treatment than before.Two groups of patients did not report adverse events.Conclusion： The use of Tamsulosin Hydrochloride combined with Longjin Tonglin Capsule was effective and safe in the treatment of chronic abacterial prostatitis.